Kura Oncology
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Below its 200-day average and near the bottom of the universe on momentum.
- Signal has read STRONG SELL for 2 weeks.
- Its last 5 Sell calls were followed by a 5% average decline over the next quarter.
- Recent price momentum is -39.0% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Short interest has fallen to 14.2% of float.
- Analyst tilt is Buy.
- Price is below its 20-day average and below its 60-day average.
- The 20-day average is below the 60-day average, a short-term downtrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2849 U.S. stocks StockVane covers.
Last computed: 2026-11-21 14:27 UTC
Data coverage: 4 of 6 factors. Missing data is not a zero score.
The radar needs all six factors. Available grades are shown below.
Valuation N/A
How expensive the stock is versus earnings, sales and its own 5-year history.
Not enough data to grade this factor.
Growth N/A
How fast revenue, profit and free cash flow are compounding.
Not enough data to grade this factor.
Profitability D+
How much profit the business keeps from each dollar of sales and capital.
| Gross margin | 99.9% | Better than 99% |
| Operating margin | -449.9% | Better than 4% |
| Net margin | -412.9% | Better than 4% |
| Return on equity | -94.8% | Better than 6% |
| Return on invested capital | -95.2% | Better than 2% |
Momentum D
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | -41.9% | Better than 9% |
| 6-month return | -38.6% | Better than 13% |
| 12-month return (ex latest month) | -11.7% | Better than 21% |
| Distance below 52-week high | 50.3% | Better than 18% |
Financial Health B+
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 6.1x | Better than 89% |
| Debt to assets | 2.8% | Better than 85% |
| Interest coverage | -183.1x | Better than 4% |
Analyst View A+
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 100.0% | Better than 77% |
| Upside to average target | 307.2% | Better than 98% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.
Performance
Key statistics
Price & volume
- Prev close
- 7.35
- Open
- 7.13
- Day range
- 6.89 - 7.37
- Avg price
- 7.05
- Volume
- 1.75M
- Turnover
- 12.35M
- Turnover ratei
- 2.31%
- Volume ratioi
- 0.72
- Amplitudei
- 6.53%
- 52-week rangei
- 6.75 - 13.90
Valuation
- P/Ei
- -2.17
- P/E (TTM)i
- -2.09
- P/Bi
- 35.44
- EPSi
- -3.18
- Book value / shi
- 0.20
- Net profit
- -292.17M
- Net assets
- 17.92M
Share structure
- Market cap
- 634.88M
- Float capi
- 524.32M
- Shares out
- 91.88M
- Float sharesi
- 75.88M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 2015-11-05
50.3% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-8.46M net over the window
Short interest
- Shares short
- 12.64M
- % of floati
- 14.21%
- Days to coveri
- 7.86
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of Kura Oncology (KURA)?
Kura Oncology last traded at 6.91. This page shows a periodic quote snapshot. Check the displayed quote time.
What is Kura Oncology's market cap?
About 634.88M.
What is the P/E ratio of Kura Oncology?
The trailing twelve-month P/E is -2.09. The Valuation tab shows it against the stock's own five-year range.
Does Kura Oncology pay a dividend?
Kura Oncology does not currently pay a regular dividend.
Is Kura Oncology a buy according to analysts?
The consensus of 9 analysts is a Buy rating, with an average 12-month price target of 28.14, which implies 307.2% upside from the current price. This is not investment advice.
What is Kura Oncology's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Kura Oncology a E (Strong Sell). Below its 200-day average and near the bottom of the universe on momentum. Not investment advice.
Quote time 2026-11-20 20:02:29 · For reference only, not investment advice and not tailored to your situation.
Kura Oncology discussion 0 comments